Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03543410 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 344
- Enrollment target
NCT03543410 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 344 participants.
The verdict
NCT03543410, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 344 participants
- Enrollment target
Study Summary
A clinical study to test the effectiveness of an investigational drug to treat people that have major depressive episodes when they have Bipolar 1 Depression
Interventions
- DRUG Placebo
- DRUG SEP-4199 200 mg
- DRUG SEP-4199 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2020-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03543410
The ClinicalTrials.gov registry entry for NCT03543410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03543410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03543410 about?
NCT03543410 is a clinical study titled "A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression". A clinical study to test the effectiveness of an investigational drug to treat people that have major depressive episodes when they have Bipolar 1 Depression
What is the current status of trial NCT03543410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 344 participants. The study started on 2018-06-26. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT03543410?
The interventions under investigation include: Placebo (DRUG), SEP-4199 200 mg (DRUG), SEP-4199 400 mg (DRUG).
Who is sponsoring clinical trial NCT03543410?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.